Scholarly Index
Erica L. Mayer
Dana-Farber Cancer Institute; 9,583 total citations; 250 total publications; best world rank #84
Dana-Farber Cancer Institute
9,583Total citations
250Total publications
44H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Advanced Breast Cancer Therapies | Lifetime | 256 | US 120 | 97.87 |
| Cancer Treatment and Pharmacology | Lifetime | 851 | US 416 | 97.76 |
| HER2/EGFR in Cancer Research | Lifetime | 662 | US 299 | 97.33 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 736 | US 317 | 89.24 |
| Breast Cancer Treatment Studies | 2021-2025 | 127 | US 46 | 98.40 |
| Advanced Breast Cancer Therapies | 2021-2025 | 84 | US 31 | 98.58 |
| HER2/EGFR in Cancer Research | 2021-2025 | 153 | US 57 | 97.71 |
| Cancer Treatment and Pharmacology | 2021-2025 | 225 | US 77 | 95.47 |
| Cancer-related Molecular Pathways | 2021-2025 | 137 | US 63 | 92.29 |
| Estrogen and related hormone effects | 2021-2025 | 440 | US 149 | 81.01 |
| PARP inhibition in cancer therapy | 2021-2025 | 961 | US 338 | 78.09 |